Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

Formosa Pharmaceuticals submitted a Clinical Trial Application (CTA) to EU regulators to run a pivotal trial for TSY-110, a biosimilar ADC candidate intended to compete with Roche’s Kadcyla® (ado-trastuzumab emtansine) in HER2-positive breast cancer. The study will assess safety, tolerability, pharmacokinetics, and immunogenicity versus the reference product, supporting potential entry into major regulated markets. Kadcyla® generated about $2.5B in global sales in 2025, making this a strategically meaningful step toward a more cost-effective oncology access proposition.

Analysis

Near term, this is a regulatory-optionality event, not a revenue event. Roche’s oncology cash flow is too diversified for a CTA filing to matter materially on its own; the equity impact only becomes meaningful if regulators implicitly validate an ADC biosimilar pathway, because that would lower the barrier for follow-on ADC copycats and compress the durability of future originator margins across the class.

The more interesting beneficiary set is the Taiwan biosimilar/CDMO ecosystem: if the comparability package holds, the market should begin to assign higher probability to manufacturing-led value creation rather than pure drug discovery. That said, ADCs are materially harder to copy than conventional mAbs, so the contrarian risk is that investors are extrapolating a clean biosimilar playbook where regulators may instead demand deeper clinical evidence, pushing launch timing out by 12-24 months.

The key inflection is not the CTA itself but whether EMA accepts a PK/immunogenicity-centered pivotal design without an efficacy burden. If it does, the 6-18 month setup improves for the local developers; if not, the story becomes a long-duration science project and the current optimism is likely overdone. Also, by the time any biosimilar reaches market, newer HER2 ADCs may have shifted prescribing, limiting the economic value of copying yesterday’s standard of care.

Key Decisions for Investors

• No immediate short in RHHBY: Kadcyla biosimilar timing is too remote for a clean earnings trade. Reassess only if EMA accepts a lean pivotal design; that would justify a tactical relative-value short vs broader pharma.
• Watchlist long 6589.TW / 6838.TW on pullbacks as a 12-24 month optionality trade on first-mover ADC biosimilar credibility. Size small: outcome is binary on regulatory scope and manufacturing comparability.
• If protocol acceptance is confirmed, consider a small long XBI / short RHHBY pair for a 3-6 month sentiment trade. The upside is a broader rerating of biosimilar-platform optionality; the risk is that Roche’s mix is too diversified for the short leg to pay.
• Set an alert for any requirement shift from PK/immunogenicity to efficacy endpoints. That would be the thesis breaker and should trigger an exit from any Taiwan biosimilar long.